Last reviewed · How we verify

Bioiberica — Portfolio Competitive Intelligence Brief

Bioiberica pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Paracetamol or oral NSAIDs excluding COX2 inhibitors Paracetamol or oral NSAIDs excluding COX2 inhibitors marketed
Droglican Droglican marketed Other

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Bioiberica:

Cite this brief

Drug Landscape (2026). Bioiberica — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bioiberica. Accessed 2026-05-15.

Related